These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10551322)

  • 21. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.
    Lehti K; Lohi J; Valtanen H; Keski-Oja J
    Biochem J; 1998 Sep; 334 ( Pt 2)(Pt 2):345-53. PubMed ID: 9716492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
    Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
    Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
    Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
    J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
    Monea S; Lehti K; Keski-Oja J; Mignatti P
    J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
    Jones JL; Glynn P; Walker RA
    J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of fibroblast-derived matrix metalloproteinase-2 by colon-cancer cells in non-contact Co-cultures.
    Ko K; Yazumi S; Yoshikawa K; Konda Y; Nakajima M; Chiba T; Takahashi R
    Int J Cancer; 2000 Jul; 87(2):165-71. PubMed ID: 10861469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation.
    Zhao H; Bernardo MM; Osenkowski P; Sohail A; Pei D; Nagase H; Kashiwagi M; Soloway PD; DeClerck YA; Fridman R
    J Biol Chem; 2004 Mar; 279(10):8592-601. PubMed ID: 14681236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells.
    Yu M; Sato H; Seiki M; Thompson EW
    Cancer Res; 1995 Aug; 55(15):3272-7. PubMed ID: 7614461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase.
    Wu YI; Munshi HG; Sen R; Snipas SJ; Salvesen GS; Fridman R; Stack MS
    J Biol Chem; 2004 Feb; 279(9):8278-89. PubMed ID: 14670950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme.
    Toth M; Hernandez-Barrantes S; Osenkowski P; Bernardo MM; Gervasi DC; Shimura Y; Meroueh O; Kotra LP; Gálvez BG; Arroyo AG; Mobashery S; Fridman R
    J Biol Chem; 2002 Jul; 277(29):26340-50. PubMed ID: 12004057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface.
    Zucker S; Hymowitz M; Conner C; DeClerck Y; Cao J
    Exp Cell Res; 2004 Feb; 293(1):164-74. PubMed ID: 14729066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation.
    Ben-Yosef Y; Lahat N; Shapiro S; Bitterman H; Miller A
    Circ Res; 2002 Apr; 90(7):784-91. PubMed ID: 11964371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.
    Okada A; Tomasetto C; Lutz Y; Bellocq JP; Rio MC; Basset P
    J Cell Biol; 1997 Apr; 137(1):67-77. PubMed ID: 9105037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase.
    Toth M; Osenkowski P; Hesek D; Brown S; Meroueh S; Sakr W; Mobashery S; Fridman R
    Biochem J; 2005 Apr; 387(Pt 2):497-506. PubMed ID: 15560752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.
    Hur JH; Park MJ; Park IC; Yi DH; Rhee CH; Hong SI; Lee SH
    J Korean Med Sci; 2000 Jun; 15(3):309-14. PubMed ID: 10895974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP).
    Zucker S; Drews M; Conner C; Foda HD; DeClerck YA; Langley KE; Bahou WF; Docherty AJ; Cao J
    J Biol Chem; 1998 Jan; 273(2):1216-22. PubMed ID: 9422789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts.
    Li H; Bauzon DE; Xu X; Tschesche H; Cao J; Sang QA
    Mol Carcinog; 1998 Jun; 22(2):84-94. PubMed ID: 9655252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
    Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
    Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma.
    Sakamoto A; Oda Y; Iwamoto Y; Tsuneyoshi M
    J Cancer Res Clin Oncol; 1999 Oct; 125(10):541-8. PubMed ID: 10473866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.